COVID D/MTA Agreement Signatory Partners*

• Queens University at Kingston
• Research St. Joseph's - Hamilton (RSJ-H)
• Sinai Health System (SHS) (formerly Mount Sinai Hospital (MSH))
• Sunnybrook Research Institute (SRI)
• The Hospital for Sick Children (SickKids)
• Thunder Bay Regional Health Sciences Centre (TBRHSC)
• Trillium Health Partners
• Unity Health Toronto (comprised of Providence Healthcare, St. Joseph's Health Centre and St. Michael's Hospital)
University Health Network (UHN)
• University of Guelph
• University of New Brunswick
• University of Ottawa
• University of Toronto (UofT)
• University of Waterloo
• University of Western Ontario, London
• University of Windsor
• Vitalite Health Network (New Brunswick Regional Health Authority)
• William Osler Health System
• Women's College Hospital
• York University (data only)

• Baycrest Health Sciences (Baycrest Centre for Geriatric Care, Baycrest Hospital, The Baycrest Day Care Centre, The Jewish Home for the Aged)
• Carleton University
• Centre for Addiction & Mental Health (CAMH)
• Hamilton Health Sciences Corporation
• Holland Bloorview Kids Rehabilitation Hospital (HBK)
• Kingston Health Sciences Centre
• Laurentian University
• Lawson Health Research Institute
• McMaster University
• Michael Garron Hospital, Toronto East Health Network
• Montfort Hospital
• North York General Hospital
• Oak Valley Health (comprised of Markham Stouffville Hospital and Uxbridge Hospital) – signatures pending
• Ontario Agency for Health and Promotion (Public Health Ontario)
• Ontario Institute for Cancer Research (OICR)
• Ottawa Hospital Research Institute (OHRI)
• Ontario Tech University
• Provincial Health Services Authority BC
• BC Cancer, BC Centre for Disease Control, and BC Children’s and Women’s Hospital

illustration of two hands shaking

UHNLEASHED

COMMERCIALIZATION AND PARTNERING SHOWCASE
By invitation only

October 10th 2024

MaRs Discovery District, Downtown Toronto

Inaugural in 2024, this exclusive event will bring together  life science industry leaders and investors to learn about the latest initiatives, resources,  innovations and partnership opportunities within Canada’s leading research hospital and medical commercialization centre – University Health Network.

Available by invitation only, this showcase will introduce UHN's new Accelerator Fund and will feature commercially viable and investment-ready life science opportunities from our hospitals and research institutes.

Event Highlights

  • Introduction of the  Accelerator Fund –  
    a premier avenue to advance leading life science discoveries to patient impact
  • Presentation of investment-ready life science opportunities
  • Presentations featuring UHN companies and new ventures
  • Overview of UHN's vast capacity and resources for product development partnerships
  • Key Speakers:
    Dr. Scott Bratman: Adela - A Commercialization Journey
    Drs. Bo Wang and Michael Brudno - The Power of AI in Healthcare / UHN AI Hub

What to Expect

Hear the latest developments directly from our researchers and spin-out companies, which are leading the charge of cutting-edge biomedical discoveries with potential to change patients' lives. You’ll also hear about the leading resources and expertise that UHN can deploy for risk-sharing partnerships.

Questions about the event? Please email robert.foldes(at)uhn.ca or ania.jones(at)uhn.ca

Speakers

Dr. Scott Bratman (Keynote)

(MD, PHD), Senior Scientist, Princess Margaret Cancer Centre and Chief Innovation Officer, Adela Inc.
Dr. Scott Bratman is a physician-scientist who is known for his innovative work of developing novel liquid biopsy methods with immense clinical impact. After graduating with a BA in Molecular Biology from Princeton University and a MD/PhD from Columbia University, Bratman conducted a groundbreaking postdoctoral research at Stanford University that advanced the practice of mutation detection within cell-free DNA. Bratman has been able to continue to produce fundamental discoveries in cell-free DNA biology, technologies, and applications as a Principal Investigator at the University of Toronto and Princess Margaret Cancer Centre. As the Chief Innovation Officer at Adela, Dr. Scott Bratman strives to help Adela develop the best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests. Their mission is to deliver innovative and accessible blood tests that harness biology to transform cancer care and improve well-being.

Dr. Bo Wang (Panelist)

Chief AI Scientist, University Health Network
Photo Credit: Tim Fraser, UHN
Dr. Bo Wang is the Chief AI scientist at the University Health Network, a tenure-track Assistant Professor in the Departments of Computer Science and Laboratory Medicine & Pathobiology at the University of Toronto and the inaugural Temerty Professor in AI Research and Education in M edicine. He also holds a CIFAR AI Chair at Vector Institute. Dr. Wang obtained his PhD from the Department of Computer Science at Stanford University in 2017.Dr. Wang’s research focuses on machine learning, computational biology, andc omputer vision, with a particular emphasis on their applications inbiomedicine.

Dr. Michael Brudno (Panelist)

Chief Data Scientist, University Health Network
Michael Brudno is the Chief Data Scientist at University Health Network. He is a Computer Scientist specializing in Computational methods for the analysis of Medical data (Computational Medicine), working as a Professor of Computer Science at the University of Toronto and the He is also a faculty member at the Vector Institute for Artificial Intelligence and the Scientific Director of HPC4Health, a private computing cloud for Ontario hospitals.

Sean Silcoff

Moderator
Sean Silcoff joined The Globe and Mail in January, 2012, following an 18-year-career in journalism and communications. He previously worked as a columnist and Montreal correspondent for the National Post and as a staff writer at Canadian Business Magazine. He began his reporting career covering courts and crime in Cornwall, Ont. www.theglobeandmail.com

Session Speakers

Cell and Gene Therapies
AI Applications, Digital Health, Data and Imaging
Product Development Resources & Rehabilitation Technologies
Devices
Therapeutics
UHN Companies / New Ventures

Event Agenda:

Auditorium
CR 3 (Upstairs)
CR 2 (Upstairs) 
TIME
ACTIVITY
8:00 AM
Registration / Breakfast / Networking
9:00 AM
Welcome
Dr. Brad Wouters, Executive VP, Science and Research, UHN

Miyo Yamashita, President & CEO, Princess Margaret Cancer Foundation and Julie Quenneville, CEO, UHN Foundation:
The Role of Philanthropy in UHN's Accelerator Fund

UHN Commercialization and Accelerator Fund Overview:

Mark Taylor, Director, Commercialization, UHN
Cell & Gene Therapies
AI Applications,
Digital Health & Data and Imaging
Sponsored by: MaRS
Product Development
Resources
10:00AM
Session -
Novel Revascularization
Cell Therapy (Dr. Gordon Keller)
Session -
Medly (UHN Company Presentation - Kirk Fergusson, CEO)
Session -
Translational Research &
Core Facilities at UHN
(Luke Brzozowski)
10:20AM
Session -
Composite liver tissue utilizing 3D bioprinting for sustainable engraftment to treat liver diseases (Dr.Shinichiro Ogawa)
Session -
Curait Medical (UHN Company
Presentation - Steven Chackowicz, CEO)
Session -
Biospecimen Services,
PM/GU Biobanks
(Heidi Wagner)
10:40AM
Session -
Inteligex (Company Presentation - Dr. Paul Bradshaw) 
Session -
“PHAROAH : a global crowd
sourcing platform for
computational pathology”
(Dr. Phedias Diamandis)
Session -
Centre for Cell and Vector
Production at UHN
(José Mangles)
11:00AM
Session -
Moving Tolerogenic ILC Therapy
Towards the Clinic
(Dr. Sarah Crome)
Session -
“Harnessing ex vivo organ perfusion
for the creation of digital lungs”
(Dr. Andrew Sage) 
Session -
STTARR Innovation Centre
(Dr. Naz Chaudary)
11:20AM
Session -
Improving cell-based immunotherapy
(Dr. Pamela Ohashi)
Session -
Altis Labs
(Douad Shah, VP Clinical Partnerships)
Session -
Advanced Molecular
Diagnostics Laboratory
(Dr. Harriet Feilotter)
11:40 AM
Session -
CapTCR/IG-seq: Immune repertoire sequencing for cancer diagnosis, monitoring, and interpreting immunotherapy response (Dr. Trevor Pugh)
Session -
Nanovista
(UHN Company Presentation - Dr. Anton Neschadim)
Session -
Quantitative Imaging for
Personalized Cancer Medicine (QIPCM): Theranostics Pipeline
(Julia Publicover)
12:15 PM
Lunch / Networking
1:00 PM
KEYNOTE - Dr. Scott Bratman, Chief Innovation Officer, Adela Inc. : Adela: A Commercialization Journey
(Sponsored by Sterne, Kessler, Goldstein & Fox PLLC)
Therapeutics
Sponsored by: Smart & Biggar
Devices
Product Development
Resources
2:00PM
Session -
Paradox Immunotherapeutics (UHN Company Presentation - Natalie Galant, CEO)
Session -
Thornhill Medical
(UHN Company Presentation)
Session -
TECHNA Engineering
(Jimmy Qiu)
2:20PM
Session -
Veritas Therapeutics
(Stephen Juvet)
Session -
Traferox Technologies Inc.
(UHN Company Presentation)
Session -
Healthcare Human Factors
(Wayne Ho)
2:40PM
Session -
QurCan Therapeutics
(UHN Company Presentation - Mohammad Amini) 
Session -
Point Surgical
(UHN Company Presentation - Darren Kramer, CEO)
Session -
Ozmosis Research
(Amit Oza/Jacqueline Amaral)
Therapeutics (Continued)
Devices (Continued) 
Rehabilitation Technologies
3:00PM  
Session -
Dantrolene reformulation for
ventricular tachycardia
(Nigel deGruyther)
Session -  
Mosquito bite needle endoscopy
(Dr. Alexandra Easson)
Session -
Functional Electrical Stimulation Technology (FES)
(Dr. Milos Popovic)
3:20PM
Session -
Targeting MYC oncoprotein activity for cancer therapy”
(Dr. Linda Penn) 
Session -
Moleculight
(UHN Company Presentation - Anil Amlani, CEO)
Session -
KITE Research Labs
(Sophia Yue Li)
3:40 PM
Refreshment Break.
Sponsored by OBIO.
4:00 PM
PANEL DISCUSSION - Bo Wang, Chief AI Scientist, UHN and CIFAR AI Chair, Vector Institute and Michael Brudno Chief Data Scientist, UHN: The Power of Data and AI in Healthcare / UHN AI Hub, Steve Schudlo, Principal, Data, AI & Digital, UHN
Moderator: Sean Silcoff, Business Reporter, Globe and Mail
4.45 PM
Closing Remarks: Dr. Brad Wouters, Executive Vice President, Science and Research, UHN
5:00 PM
Cocktail Reception and Networking
Sponsored by Norton Rose Fulbright Canada
Auditorium
CR 3 (Upstairs)
CR2 (Upstairs)
TIME
8:00 AM
9:00 AM
TOPICS
10:00 AM
10:20 AM
10:40 AM
11:00 AM
11:20 PM
11:40 AM
12:15 PM
1:00 PM
TOPICS
2:00 PM
2:20 PM
2:40 PM
TOPICS
3:00 PM
3:20 PM
3:40 PM
4:00 PM
4:45 PM
5:00 PM
illustration of two hands shaking

Accelerator Fund

The Accelerator Fund offers significant capital to help early-stage technologies advance. The fund is designed to expedite the promise of innovations within UHN and partner organizations to get them to patients faster. This fund will help those who need the funding to enhance their commercial potential and bring new medical products, devices, and therapies to the market more swiftly.

Learn More

Launch Sponsors

Event Sponsors